{"url_path":"/sec/lrmr/8-k/2026-06-29/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1374690/0001193125-26-286780-index.html","accession_number":"0001193125-26-286780","cik":"0001374690","ticker":"LRMR","issuer_name":"Larimar Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1374690/0001193125-26-286780-index.html","primary_entity_key":"0001374690","primary_entity_name":"Larimar Therapeutics, Inc."},"word_count":141,"has_tables":true,"body_markdown":"## Item 8.01 Other Events.\n\nPress Release\n\n \n\nOn June 29, 2026, Larimar Therapeutics, Inc. (the “Company”) issued a press release announcing (i) that it has submitted the first module of the Company’s rolling Biologics License Application submission to the Food and Drug Administration for accelerated approval of nomlabofusp and (ii) positive data from the Company’s ongoing long-term open label study evaluating daily subcutaneous injections of nomlabofusp in adolescent and adult patients with Friedreich’s ataxia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nInvestor Presentation\n\n \n\nOn June 29, 2026, the Company will host a conference call to discuss a regulatory update and use a slide presentation in conjunction with the call. A copy of the presentation is filed herewith as Exhibit 99.2, and incorporated herein by reference."}